Literature DB >> 14573361

Domain antibodies: proteins for therapy.

Lucy J Holt1, Chris Herring, Laurent S Jespers, Benjamin P Woolven, Ian M Tomlinson.   

Abstract

Occurring naturally in "heavy chain" immunoglobulins from camels, and now produced in fully human form, domain antibodies (dAbs) are the smallest known antigen-binding fragments of antibodies, ranging from 11 kDa to 15 kDa. dAbs are the robust variable regions of the heavy and light chains of immunoglobulins (VH and VL respectively). They are highly expressed in microbial cell culture, show favourable biophysical properties including solubility and temperature stability, and are well suited to selection and affinity maturation by in vitro selection systems such as phage display. dAbs are bioactive as monomers and, owing to their small size and inherent stability, can be formatted into larger molecules to create drugs with prolonged serum half-lives or other pharmacological activities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573361     DOI: 10.1016/j.tibtech.2003.08.007

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  101 in total

1.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

2.  Targeted ion parking for the quantitation of biotherapeutic proteins: concepts and preliminary data.

Authors:  J Larry Campbell; J C Yves Le Blanc
Journal:  J Am Soc Mass Spectrom       Date:  2010-08-27       Impact factor: 3.109

Review 3.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

Review 4.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 5.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

6.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Authors:  Sven Jähnichen; Christophe Blanchetot; David Maussang; Maria Gonzalez-Pajuelo; Ken Y Chow; Leontien Bosch; Sindi De Vrieze; Benedikte Serruys; Hans Ulrichts; Wesly Vandevelde; Michael Saunders; Hans J De Haard; Dominique Schols; Rob Leurs; Peter Vanlandschoot; Theo Verrips; Martine J Smit
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 7.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

8.  Integrated mimicry of B cell antibody mutagenesis using yeast homologous recombination.

Authors:  Jeffrey S Swers; Yik A Yeung; K Dane Wittrup
Journal:  Mol Biotechnol       Date:  2011-01       Impact factor: 2.695

9.  Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.

Authors:  Weizao Chen; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

10.  Identification of novel tumor antigens with patient-derived immune-selected antibodies.

Authors:  Daniel Rodriguez-Pinto; Jason Sparkowski; Martin P Keough; Kathryn N Phoenix; Frank Vumbaca; David K Han; Eckart D Gundelfinger; Philip Beesley; Kevin P Claffey
Journal:  Cancer Immunol Immunother       Date:  2008-06-21       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.